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Aim. To evaluate the role of contrast-enhanced intraoperative ultrasound (CE-IOUS) during liver surgery in the detection and
management of liver lesions in patients with hepatocellular carcinoma (HCC). Materials and Methods. From December 2016 to
December 2017, 50 patients with HCC, who were candidates for liver resection, were evaluated with intraoperative ultrasound
(IOUS). For all patients, MRI and/or CT were performed before surgery. During surgery, IOUS was performed after liver
mobilization, and when nodules that had not been detected in the preoperative MRI and/or CT were observed, CE-IOUS scans
were carried out with the dual purpose of better characterizing the unknown lesion and discovering new lesions. Results. In 12
patients, IOUS showed 14 nodules not detected by preoperative MRI and/or CT, before surgery. Out of the 12 lesions, five
presented vascular features compatible with those of malignant HCC to the evaluation with CE-IOUS and four of these were
simultaneously treated with intraoperative radiofrequency ablation (RFA). +e fifth lesion was resected by the surgeon. +e
remaining nine lesions recognized by IOUS were evaluated as benign at CE-IOUS and considered regenerative nodules. +e last
diagnosis was confirmed during follow-up obtained by means of CT and/or MRI after 1, 3, 6, or 12months. Conclusion. In our
experience, CE-IOUS is a useful diagnostic tool in both benign pathologies, such as regenerative nodules, and malignant liver
lesions. +e advantage of this approach is the possibility of intraoperatively characterizing, based on vascularization patterns,
lesions that could not be diagnosed by preoperative imaging, resulting in modification of the surgical therapy decision and
expansion of the resection or intraoperative ablation.
1. Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
malignancy and is one of the main causes of cancer-related
death worldwide. +is condition is expected to increase
further in upcoming years [1, 2]. Modern cross-sectional
imaging plays a crucial role in detection and characterization
of focal liver lesions, being essential before starting any type
of therapy. Moreover, imaging has a significant role during
local ablative treatments and on the assessment of the ef-
ficacy of percutaneous procedures [3]. +e management of
HCC involves multiple disciplines including hepatology,
surgery, diagnostic and interventional radiology, oncology,
and pathology [4, 5].
Nowadays, both contrast-enhanced computed tomog-
raphy (CE-CT) andmagnetic resonance imaging (MRI) with
or without liver-specific contrast agent [6] have greatly
improved the detection and characterization of liver tumors.
Recent innovations such as contrast-enhanced ultra-
sound imaging (CEUS) [7, 8] have raised the standards for
HCC diagnosis as demonstrated by numerous studies
[9, 10].
Hepatic resection is part of the conventional treatment for
patients with primary liver cancers; however, the majority of
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HCCs are not suitable for curative resection at the time of
diagnosis [11].
Intraoperative ultrasound (IOUS) is an important tool
used during surgical treatment of liver cancers, and par-
ticularly in patients with HCC [12, 13], especially when
palpable tumors are found intraoperatively and it is man-
datory to decide whether resection of malignant lesions is
necessary or a lesion appears benign [14].
Proper collaboration between surgeons and interven-
tional radiologists during liver resection in HCC patients is
necessary, in order to increase chances of radical treatment
in patients with multinodular HCC. Although liver resection
represents the first choice of treatment for primary liver
cancer, giving the patient the best chance of long-term
survival [15], extensive resections of hepatic parenchyma
expose patients to the risk of posthepatectomy liver failure
(PHLF) associated with a high frequency of postoperative
complications, mortality, and an increased length of hospital
stay [16].
+us, radiofrequency ablation (RFA), a widely accepted
minimally invasive technique able to destroy tumor effec-
tively and safely [17, 18], should be available during surgical
liver resection, in order to save resection of unnecessary
healthy hepatic parenchyma.
However, incorrect targeting on imaging could cause
inadequate placement of the RFA needle which, in turn,
could lead to the need of more treatment sessions or more
frequent local recurrence after RFA [19]. It has been
demonstrated that CE-IOUS is an accurate diagnostic
technique in detecting and characterizing focal liver lesion,
and its use in surgical navigation has already been reported
in many studies [20–24].
+e aim of this study is to evaluate the role of CE-IOUS
during liver surgery in the detection and management of
liver lesions, as it is known that the technique helps to better
characterize the already known lesions. Noteworthy to
mention is the fact that not all lesions detected by CE-IOUS
in cirrhotic patients with HCC are malignant [21]; therefore,
the possibility of intraoperatively characterizing lesions not
evident in preoperative imaging is fundamental to guarantee
these patients the best therapeutic strategy, performing
intraoperative RFA or expanding resection, and more ac-
curate follow-up.
2. Materials and Methods
2.1. Patients Selection. +is is a retrospective study conducted
with the approval of the ethics committee, and informed
consents were obtained from all patients. From December 2016
toDecember 2017, 58 patients with chronic liver disease affected
by HCC and who were candidates for liver resection were
included. Based on the exclusion criteria, 8 patients, lost in
follow-up, were excluded from the study. CE-IOUS was per-
formed in 12 cirrhotic patients who presented lesions not ev-
ident in preoperative imaging with IOUS evaluation. Cirrhosis
was documented by the histological evaluation performed
during liver follow-up. +e etiology of cirrhosis was hepatitis C
in 5 patients, hepatitis B and NASH in 1 patient, alcoholic
hepatitis in 2 patients, and cryptogenic hepatitis in 4 patients.
2.2. Preoperative Imaging. All patients underwent CT or
MRI or both with contrast medium administration before
surgery. Contrast-enhanced MRI examinations were per-
formed with a 1.5 T imaging system (Philips Achieva) using
T1-weighted (W) turbo spin-echo (TSE), T2-W TSE se-
quences integrated with fat suppression, dual sequences, and
diffusion-weighted imaging (DWI), following an in-
travenous bolus of 0.1mmol gadoteridol (ProHance, Bracco
SpA, Milan, Italy) per kg of body weight administered at a
rate of 2mL/s and 20mL of sodium chloride solution. CE-
CT scans were performed with a GE Revolution EVO (GE
Healthcare, Milan, Italy) pre- and postintravenous injection
of 110–130mL iopamidol (Iopamiro (300mgI/ml), Bracco
SpA, Milan, Italy) with helical scan, 0.6 sec rotation time,
pitch 0.9, 120 kV, 250mA, and image thickness of 2.50mm.
MRI and CTdata were acquired in three phases: the hepatic
arterial, the portal venous, and the equilibrium. Intra-
operative ultrasound patients were treated with open sur-
gery. During surgery, IOUS was performed after liver
mobilization and, when nodules that had not been detected
in the preoperative MRI and/or CTwere observed, CE-IOUS
scans were carried out with the dual purpose of better
characterizing the unknown lesion and discovering new
lesions. CE-IOUS was performed with MyLab Twice (Esaote
SpA, Genoa, Italy), equipped with a IOT 342 linear trans-
ducer (Top-View) that covering a wider frequency range
(3–11MHz). All lesions were counted and mapped. CE-
IOUS was performed with intravenous injection through a
peripheral vein of 5mL ultrasound contrast agent composed
of sulphur hexafluoride microbubbles stabilized by a
phospholipid shell (SonoVue, Bracco SpA, Milan, Italy).
Immediately after the injection, 20mL saline was injected in
the same way.+e arterial, portal, and late phases of contrast
enhancement were recorded and analyzed. +e late phase
ended with disappearance of the microbubbles from the
circle occurring after 240–360 seconds from the start of the
examination [7]. Following the first US contrast medium
injection, a full examination of the liver was carried out,
segment by segment, to search for new lesions. Only in the
case of the patient with two lesions in the two different lobes,
two administrations of ultrasound contrast agent, each
2.5mL, were performed, taking care to wait 6minutes be-
tween one administration and another in order to avoid
artifacts. After any RFA, a further CE-IOUS was performed.
+ere were no artifacts or need for flash because a sufficient
amount of time elapsed between the CE-IOUS pre- and
posttreatment with radiofrequency. +e maximum total
dose allowed was 3 doses of 5.0mL.
2.3. Histological Analysis and Intraoperative Radiofrequency
,ermoablation. For all lesions considered malignant at
IOUS and CE-IOUS, biopsy and histological examination
were performed.+ey were treated with surgical resection or
with intraoperative RFA. RFA was performed using the RF
generator 3000 (Boston Scientific) by positioning the active
tip of the needle (LeVeen 14G) into the lesion with 4 cm of
displayed hooks. +e RFA procedures were made according
to setting of manufacturer up to a final output with roll-off
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obtained two times. +e outcomes of the treatment with
RFA were monitored intraoperatively with further ultra-
sound contrast medium administration and subsequently
with follow-up obtained by means of CTand/or MRI after 1,
3, 6, or 12months.
3. Results
Fifty patients were evaluated with IOUS during surgical
resection for HCC. In 12 cirrhotic patients, IOUS showed
focal lesions not detected by preoperative MRI and/or CT,
before surgery. +e average age of the patients (six women
and six men) was 69.4 years (range 52–78 years).
IOUS during hepatic resection of HCC demonstrated 14
nodules. One patient had two lesions in two different lobes,
and another patient had two suspected lesions close to each
other in the same lobe. +ese newly detected lesions were
evaluated during liver surgery using CE-IOUS, in an attempt
to discriminate benign frommalignant lesions and decide on
treatment in real time. CE-IOUS data were analyzed based
on the lesions’ wash-in and washout during the arterial,
portal venous, and late venous phases. Depending on the
vascularization patterns, lesions were characterized as ma-
lignant or benign and, if possible, a differential diagnosis was
given. Signs of malignancy were considered: arterial phase
hyperenhancement followed by late (>60 s) washout [25].
+e CE-IOUS allowed us to characterize 14 nodules, with an
average size of 10.2mm (range 7.2mm–24mm), five of
which present CE-IOUS vascular features compatible with
those of malignant HCC (Figures 1 and 2) and were con-
firmed by biopsy and histological examination. Four of the
five malignant lesions detected by CE-IOUS were simulta-
neously treated with intraoperative RFA, and their complete
ablation was intraoperatively evaluated with further ultra-
sound contrast medium administration. +e fifth lesion was
resected by the surgeon. +e remaining nine lesions rec-
ognized by IOUS were evaluated as benign at CE-IOUS and
considered regenerative nodules (Figure 3). Since they were
small (≤1 cm), it was decided to follow up them. All patients
underwent follow-up with CT and/or MRI at 1, 3, 6, and
12months. +e regenerative nodules were confirmed as
such, presenting no variation in size and vascularization
during follow-up. Also, the complete excision and the ab-
sence of disease residues after RFA were confirmed in the
follow-up.
4. Discussion
Preoperative hepatic imaging diagnosis, such as CT, MRI,
and positron emission tomography (PET), has improved
considerably in recent years. In 2004, Sahani et al. [26]
claimed that MRI is as sensitive as IOUS in depicting hepatic
lesions before hepatic resection (86.7% and 94.3%, re-
spectively). Moreover, Huf et al. [27] reported no statistical
significance of CEUS and MRI regarding the general dif-
ferential diagnosis for hepatic tumors. In this study, we
highlighted the importance of the presence of interventional
radiologist with CE-IOUS and RFA experience during liver
resection procedures, in order to perform intraoperative
ultrasound, able to ensure optimized liver surgery and able
to provide an alternative treatment for unexpected new liver
lesions unsuitable for resection. During the long process of
the carcinogenesis of HCC, the neovascularization in small
lesions may be invisible with the current imaging approaches
[28]. Echogenicity of the lesions often changes especially
after therapy, embolization, or RFA, which makes it difficult
to identify the typical signs of malignancy, e.g., hypoechoic,
irregular, and sometimes hypoechoic rim in the periphery of
the lesion [29]. Early hypervascularization of HCC lesions in
the arterial phase and typical washout of contrast starting in
the portal venous phase and continuing in the late phase
could be shown only by CEUS. In the CE-IOUS study, HCC
lesions are characterized by hyperenhancement during the
arterial phase and microbubbles’ washout during the portal
and late phases [30]. Compared to normal vessels, tumor
vessels are tortuous, excessively branched, and short-
circuited; thus, overall tumor vasculature appears highly
disorganized [31].
+e imaging characteristics typical for HCC are difficult
to find in small lesions. With the limit of preoperative di-
agnostic imaging criteria, the Transplantation Network
(OPTN)/United Network for Organ Sharing (UNOS) [32]
and the Liver Imaging Reporting and Data System (US LI-
RADS) [33] suggested not to diagnose, as HCC, lesions<1 cm in diameter.
CE-IOUS can have difficulty in visualizing some regions
of the liver even in a mobilized liver (subdiaphragmatic
segment VIII). Moreover, special ultrasound devices and a
highly experienced examiner are needed to acquire high-
quality contrast-enhanced ultrasound scans. In addition,
ultrasound is a depth-dependent imaging modality that can
reach its limits particularly in overweight patients. CE-IOUS
can ensure good visualization of the liver even in overweight
patients but is subject to time constraints due to the surgical
situation.
+is study shows that the use of high definition tech-
nique of CE-IOUS with multifrequency probes led to rel-
evant changes in the surgical strategy for malignant liver
tumors.
SonoVue® does not impair kidney function as contrastagents used for CE-CTor CE-MRI; therefore, it can be used
also in case of reduced creatinine clearance or even kidney
failure. +e main contraindication for the use of SonoVue®is intolerance for contrast agent component that is very rare,
so it is important to specifically exclude this intolerance
when obtaining informed consent from the patient.
Results published by Loss et al. [34] showed that in a
population of 50 patients, in 28 patients, additional lesions
were found using CE-IOUS (mean tumor size of 8mm, range
4–12mm). Authors described a change in surgical strategy or
the intraoperative application of RFA in 27 patients (54%),
resulting in modification of therapy due to additional liver
lesions.+e largest andmost comprehensive analysis of CEUS
in the diagnosis of liver tumors is the multicenter prospective
DEGUM study [35, 36]. It was able to be shown that CEUS
has high diagnostic value for all benign and malignant liver
tumor entities. +e early detection of small HCC allows new
chances for a successful surgery [37].
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We observed that CE-IOUS provided an advantage to
characterize lesions not detected by presurgical imaging,
resulting in changes of the surgical therapy decision and en-
largement of the resection or the application of intraoperative
ablation. Particularly, we detected 14 new lesions, 5 of them
classified as malignant based on CE-IOUS findings and con-
firmed by biopsy and histological examination. In our expe-
rience, the evidence of an additional malignant lesion modified
the planned surgical strategy in a patient. In other cases of
malignant lesions, in which it was not possible to extend liver
resections, radiofrequency ablation (RFA) was done.
RFA has a very important role as an alternative to
surgery. Some physicians prefer RFA to surgical resection
for the treatment of small HCC even when the patient is
eligible for surgery because of the relatively low morbidity
and high quality of life [38, 39]. RFA is recommended for
the treatment of HCC with a maximum diameter of 3 cm in
patients with no more than three tumor masses, in whom
surgery is contraindicated [11]. +e technical effectiveness
of RFA depends on the correct targeting of the nodule on
US and adequate placement of the RFA needle [19]. CEUS
has been increasingly used for detection, characterization,
(a) (b)
(c) (d)
Figure 1: Example of typical vasculature features of CE-IOUS compatible with a malignant nodule of HCC that showed early contrast
enhancement and fast washout: (a) early arterial phase; (b) arterial phase; (c) portal phase; (d) late phase.
(a) (b) (c)
Figure 2: A particular CE-IOUS case showed a peripheral arterial hyperenhancing and hypoechogenic enhancing in the portal and late
phases without contrast enhancement in the central area in all phases for hematic and colliquative necrosis component: (a) arterial phase;
(b) portal phase; (c) late phase.
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and planning of therapeutic interventions of liver tumors
[9, 10].
As reported, RF ablation guided by a second-generation
microbubble-enhanced USmay be easier to perform andmay
be an efficient approach to liver malignancies that are not
clearly depicted on B-mode US [11]. CE-IOUS has been
reported to be useful also for RFAmonitoring [40–42]. In our
case, the complete ablation assessed intraoperatively with CE-
IOUSwas confirmed during follow-up with CTand/orMRI at
1, 3, 6, or 12months. Also, follow-up confirms that the re-
generative nodules maintained benign criteria in imaging
over time, and this allows to understand how the IO-CEUS
compared to the IO-US allows to effectively distinguish be-
nign from malignant nodules and thus subjecting to the RF
treatment a smaller number of lesions than all those evi-
denced with the IOUS, reducing complications and additional
costs in terms of quality of life and economic health.
+is study illustrates that intraoperating CE-IOUS al-
lows to accurately detect and characterize liver lesions not
evident in preoperative CT and MRI and that it is a useful
instrument able to provide additional information during
surgery and help in the RFA procedure. +e results obtained
with CE-IOUS reduce the diagnostic uncertainties and help
in guiding the therapeutic choice, increasing the chances of
obtaining the nodule’s radical resection. Other than the
improved characterization of already known and new le-
sions, CE-IOUS allowed to characterize also benign lesions
as nodules of regeneration. +is aspect is crucial regarding
the clinical-instrumental follow-up of these nodules because,
by knowing the regenerative nature of these nodules, it is
possible to perform a more targeted follow-up, which is
significant in dealing with cirrhotic patients that already
need a thorough instrumental monitoring, especially when
considering their history of HCC. +ere were some limi-
tations in this study including its retrospective approach and
the single-center design; moreover, the sample was too small
to obtain significant statistical data. For these reasons, more
studies are needed to further assess this technique.
5. Conclusion
+is study demonstrated that CE-IOUS is a useful diagnostic
tool in both benign and malignant liver lesions. It provides
more information than the simple IOUS on the charac-
teristics of the lesion with a dynamic study. In this way, the
advantage of this approach is the possibility of intra-
operatively characterizing, based on the vascularization
patterns, lesions that could not be diagnosed by preoperative
imaging, resulting in modification of the surgical therapy
decision and expansion of the resection or intraoperative
ablation.
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+e data used to support the findings of this study are
available from the corresponding author upon request.
Conflicts of Interest
+e authors declare that they have no conflicts of interest.
References
[1] A. P. Venook, C. Papandreou, J. Furuse, and L. Ladron de
Guevara, “+e incidence and epidemiology of hepatocellular
carcinoma: a global and regional perspective,”,e Oncologist,
vol. 15, no. 4, pp. 5–13, 2010.
[2] D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Estimating the
world cancer burden: globocan 2000,” International Journal of
Cancer, vol. 94, no. 2, pp. 153–156, 2001.
[3] V. Vilgrain, “Advancement in HCC imaging: diagnosis,
staging and treatment efficacy assessments,” Journal of
Hepato-Biliary-Pancreatic Sciences, vol. 17, no. 4, pp. 374–379,
2010.
[4] M. Omata, L. A. Lesmana, R. Tateishi et al., “Asian pacific
association for the study of the liver consensus recommen-
dations on hepatocellular carcinoma,” Hepatology In-
ternational, vol. 4, no. 2, pp. 439–474, 2010.
[5] A. Forner and J. Bruix, “Ablation for hepatocellular carci-
noma: is there need to have a winning technique?,” Journal of
Hepatology, vol. 52, no. 3, pp. 310–312, 2010.
[6] A. Orlacchio, F. Chegai, S. Fabiano et al., “Role of MRI with
hepatospecific contrast agent in the identification and char-
acterization of focal liver lesions: pathological correlation in
explanted livers,” La Radiologia Medica, vol. 121, no. 7,
pp. 588–596, 2016.
[7] M. Claudon, C. F. Dietrich, D. O. Cosgrove et al., “Guidelines
and good practise recommendations for contrast enhanced
(a) (b) (c)
Figure 3: A typical hypoenhancement in all phases of regenerative nodules: (a) arterial phase; (b) portal phase; (c) late phase.
Journal of Oncology 5
ultrasound (CEUS) in the liver—update 2012,” Ultraschall in
Med, vol. 34, no. 1, pp. 11–29, 2013.
[8] C. P. Nolsoe and T. Lorentzen, “International guidelines for
contrast-enhanced ultrasonography: ultrasound imaging in
the new millennium,” Ultrasonography, vol. 35, no. 2,
pp. 89–103, 2016.
[9] V. Salvatore and L. Bolondi, “Clinical impact of ultrasound-
related techniques on the diagnosis of focal liver lesions,”
Liver Cancer, vol. 1, no. 3-4, pp. 238–246, 2012.
[10] I. Joo and B. I. Choi, “New paradigm for management of
hepatocellular carcinoma by imaging,” Liver Cancer, vol. 1,
no. 2, pp. 94–109, 2012.
[11] Y. Minami and M. Kudo, “Review of dynamic contrast-en-
hanced ultrasound guidance in ablation therapy for hepato-
cellular carcinoma,” World Journal of Gastroenterology,
vol. 17, no. 45, pp. 4952–4959, 2011.
[12] Q. Lu, Y. Luo, C.-X. Yuan et al., “Value of contrast-enhanced
intraoperative ultrasound for cirrhotic patients with hepa-
tocellular carcinoma: a report of 20 cases,” World Journal of
Gastroenterology, vol. 14, no. 25, pp. 4005–4010, 2008.
[13] M. Donadon and G. Torzilli, “Intraoperative ultrasound in
patients with hepatocellular carcinoma: from daily practice to
future trends,” Liver Cancer, vol. 2, no. 1, pp. 16–24, 2013.
[14] M. Donadon, G. Costa, and G. Torzilli, “State of the art of
intraoperative ultrasound in liver surgery: current use for
staging and resection guidance,” Ultraschall in der Medizin,
vol. 35, no. 6, pp. 500–511, 2014.
[15] R. T.-P. Poon, S.-T. Fan, C.-M. Lo et al., “Improving survival
results after resection of hepatocellular carcinoma: a pro-
spective study of 377 patients over 10 years,” Annals of
Surgery, vol. 234, no. 1, pp. 63–70, 2001.
[16] M. Shoup, M. Gonen, M. D’Angelica et al., “Volumetric
analysis predicts hepatic dysfunction in patients undergoing
major liver resection,” Journal of Gastrointestinal Surgery,
vol. 7, no. 3, pp. 325–330, 2003.
[17] A. R. Gillams, “Radiofrequency ablation in the management
of liver tumours,” European Journal of Surgical Oncology
(EJSO), vol. 29, no. 1, pp. 9–16, 2003.
[18] M. Kudo, “Radiofrequency ablation for hepatocellular carci-
noma: updated review in 2010,” Oncology, vol. 78, no. Suppl 1,
pp. 113–124, 2010.
[19] T. Minami, Y. Minami, H. Chishina et al., “Combination
guidance of contrast-enhanced US and fusion imaging in
radiofrequency ablation for hepatocellular carcinoma with
poor conspicuity on contrast-enhanced US/fusion imaging,”
Oncology, vol. 87, no. s1, pp. 55–62, 2014.
[20] K. Sato, S. Tanaka, Y. Mitsunori et al., “Contrast-enhanced
intraoperative ultrasonography for vascular imaging of he-
patocellular carcinoma: clinical and biological significance,”
Hepatology, vol. 57, no. 4, pp. 1436–1447, 2013.
[21] J. B. Kruskal and R. A. Kane, “Intraoperative US of the liver:
techniques and clinical applications,” Radiographics, vol. 26,
no. 4, pp. 1067–1084, 2006.
[22] A. Alzaraa, G. Gravante, W. Y. Chung et al., “Contrast-en-
hanced ultrasound in the preoperative, intraoperative and
postoperative assessment of liver lesions,” Hepatology Re-
search, vol. 43, no. 8, pp. 809–819, 2013.
[23] E. Leen, P. Ceccotti, S. J. Moug et al., “Potential value of
contrast-enhanced intraoperative ultrasonography during
partial hepatectomy for metastases,” Annals of Surgery,
vol. 243, no. 2, pp. 236–240, 2006.
[24] I. Joo, “+e role of intraoperative ultrasonography in the
diagnosis and management of focal hepatic lesions,” Ultra-
sonography, vol. 34, no. 4, pp. 246–257, 2015.
[25] P. R. Galle, A. Forner, and J. M. Llovet, “EASL clinical practice
guidelines: management of hepatocellular carcinoma,” Jour-
nal of Hepatology, vol. 69, no. 1, pp. 182–236, 2018.
[26] D. V. Sahani, S. P. Kalva, K. K. Tanabe et al., “Intraoperative
US in patients undergoing surgery for liver neoplasms:
comparison with MR imaging,” Radiology, vol. 232, no. 3,
pp. 810–814, 2004.
[27] S. Huf, N. Platz Batista da Silva, I.Wiesinger et al., “Analysis of
liver tumors using preoperative and intraoperative contrast-
enhanced ultrasound (CEUS/IOCEUS) by radiologists in
comparison to magnetic resonance imaging and histopa-
thology,” Ro¨Fo—Fortschritte auf dem Gebiet der
Ro¨ntgenstrahlen und der bildgebenden Verfahren, vol. 189,
no. 5, pp. 431–440, 2017.
[28] S. Gaiani, N. Celli, F. Piscaglia et al., “Usefulness of contrast-
enhanced perfusional sonography in the assessment of he-
patocellular carcinoma hypervascular at spiral computed
tomography,” Journal of Hepatology, vol. 41, no. 3,
pp. 421–426, 2004.
[29] C. F. Dietrich, W. Kratzer, D. Strobe et al., “Assessment of
metastatic liver disease in patients with primary extrahepatic
tumors by contrast-enhanced sonography versus CT and
MRI,” World Journal of Gastroenterology, vol. 12, no. 11,
pp. 1699–1705, 2006.
[30] S. H. Morin, A. K. Lim, J. F. Cobbold, and S. D. Taylor-
Robinson, “Use of second generation contrast-enhanced ul-
trasound in the assessment of focal liver lesions,” World
Journal of Gastroenterology, vol. 13, no. 45, pp. 5963–5970,
2007.
[31] S. Tanaka and S. Arii, “Current status and perspective of
antiangiogenic therapy for cancer: hepatocellular carcinoma,”
International Journal of Clinical Oncology, vol. 11, no. 2,
pp. 82–89, 2006.
[32] O.P.a.T. Network, “HRSA/OPTN. Policy 3.6 organ distri-
bution: allocation of livers,” 2017, https://optn.transplant.
hrsa.gov/media/1200/optn_policies.pdf.
[33] K. M. Elsayes, A. Z. Kielar, M. M. Agrons et al., “Liver imaging
reporting and data system: an expert consensus statement,”
Journal of Hepatocellular Carcinoma, vol. 4, pp. 29–39, 2017.
[34] M. Loss, J. Schneider, W. Uller et al., “Intraoperative high
resolution linear contrast enhanced ultrasound (IOUS) for
detection of microvascularization of malignant liver lesions
before surgery or radiofrequeny ablation,” Clinical Hemor-
heology andMicrocirculation, vol. 50, no. 1-2, pp. 65–77, 2012.
[35] K. Seitz, D. Strobel, T. Bernatik et al., “Contrast-Enhanced
Ultrasound (CEUS) for the characterization of focal liver
lesions—prospective comparison in clinical practice: CEUS
vs. CT (DEGUM multicenter trial). Parts of this manuscript
were presented at the Ultrasound Dreilandertreffen 2008,
Davos,” Ultraschall in der Medizin—European Journal of
Ultrasound, vol. 30, no. 4, pp. 383–389, 2009.
[36] D. Strobel, K. Seitz, W. Blank et al., “Contrast-enhanced
ultrasound for the characterization of focal liver
lesions—diagnostic accuracy in clinical practice (DEGUM
multicenter trial),” Ultraschall in der Medizin—European
Journal of Ultrasound, vol. 29, no. 5, pp. 499–505, 2008.
[37] G. Torzilli, F. Procopio, F. Botea et al., “One-stage ultra-
sonographically guided hepatectomy for multiple bilobar
colorectal metastases: a feasible and effective alternative to the
2-stage approach,” Surgery, vol. 146, no. 1, pp. 60–71, 2009.
[38] J.-E. Kim, Y.-s. Kim, H. Rhim et al., “Outcomes of patients
with hepatocellular carcinoma referred for percutaneous
radiofrequency ablation at a tertiary center: analysis focused
on the feasibility with the use of ultrasonography guidance,”
6 Journal of Oncology
European Journal of Radiology, vol. 79, no. 2, pp. e80–e84,
2011.
[39] N. P. B. da Silva, L. P. Beyer, M. C. Hottenrott et al., “Efficiency
of contrast enhanced ultrasound for immediate assessment of
ablation status after intraoperative radiofrequency ablation of
hepatic malignancies,” Clinical Hemorheology and Microcir-
culation, vol. 66, no. 4, pp. 357–368, 2017.
[40] P. Wiggermann, I. Zuber-Jerger, Y. Zausig et al., “Contrast-
enhanced ultrasound improves real-time imaging of ablation
region during radiofrequency ablation: preliminary results,”
Clinical Hemorheology and Microcirculation, vol. 49, no. 1–4,
pp. 43–54, 2011.
[41] Y. Minami, M. Kudo, T. Kawasaki, H. Chung, C. Ogawa, and
H. Shiozaki, “Treatment of hepatocellular carcinoma with
percutaneous radiofrequency ablation:usefulness of contrast
harmonic sonography for lesions poorly defined with B-mode
sonography,” American Journal of Roentgenology, vol. 183,
no. 1, pp. 153–156, 2004.
[42] L. Solbiati, T. Ierace, M. Tonolini, and L. Cova, “Guidance and
monitoring of radiofrequency liver tumor ablation with con-
trast-enhanced ultrasound,” European Journal of Radiology,
vol. 51, pp. S19–S23, 2004.
Journal of Oncology 7
